This intricate relationship gains particular significance in advanced cancers, including Non-Small Cell Lung Cancer (NSCLC), where TP53 gene mutations and HIF-1 activation in hypoxic regions are frequently observed (Amelio et al. 2018). This evidence concerns the gene TP53 and cancer.